Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Roncolato, FT (author)

O'Connell, R (author)

Joly, F (author)

show more...

Lanceley, A (author)

Hilpert, F (author)

Okamoto, A (author)

Aotani, E (author)

Pignata, S (author)

Donnellan, PP (author)

Oza, AM (author)

Avall-Lundqvist, E (author)

Berek, JS (author)

Sjoquist, KM (author)

Gillies, K (author)

Butow, P (author)

Stockler, MR (author)

King, MT (author)

Friedlander, M (author)

show less...

American Society of Clinical Oncology (ASCO), 2015

2015

English.

In: JOURNAL OF CLINICAL ONCOLOGY. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 33:15

Related links:

http://kipublication...

show more...

https://doi.org/10.1...

show less...

• Conference paper (other academic/artistic)